550 related articles for article (PubMed ID: 21914503)
1. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer.
Goulart B; Ramsey S
Value Health; 2011; 14(6):836-45. PubMed ID: 21914503
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z
Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
[TBL] [Abstract][Full Text] [Related]
4. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.
Montero AJ; Avancha K; Glück S; Lopes G
Breast Cancer Res Treat; 2012 Apr; 132(2):747-51. PubMed ID: 22200867
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan.
Ahn MJ; Tsai CM; Hsia TC; Wright E; Chang JW; Kim HT; Kim JH; Kang JH; Kim SW; Bae EJ; Kang M; Lister J; Walzer S
Asia Pac J Clin Oncol; 2011 Jun; 7 Suppl 2():22-33. PubMed ID: 21585705
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
Shiroiwa T; Fukuda T; Tsutani K
Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
[TBL] [Abstract][Full Text] [Related]
7. Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada.
Hedden L; Kennecke H; Villa D; Johnston K; Speers C; Kovacic L; Renouf DJ; Peacock S
Eur J Cancer; 2012 Sep; 48(13):1969-76. PubMed ID: 22325838
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer.
Thongprasert S; Permsuwan U; Ruengorn C; Charoentum C; Chewaskulyong B
Asia Pac J Clin Oncol; 2011 Dec; 7(4):369-75. PubMed ID: 22151987
[TBL] [Abstract][Full Text] [Related]
9. Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
Kovic B; Xie F
J Clin Oncol; 2015 Jul; 33(20):2296-302. PubMed ID: 26014296
[TBL] [Abstract][Full Text] [Related]
10. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.
Wan X; Luo X; Tan C; Zeng X; Zhang Y; Peng L
Cancer; 2019 Oct; 125(20):3526-3534. PubMed ID: 31287562
[TBL] [Abstract][Full Text] [Related]
11. An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.
Nuijten MJ; Aultman R; Carpeño Jde C; Vergnenègre A; Chouaid C; Walzer S; Siebert U
Curr Med Res Opin; 2011 Nov; 27(11):2193-201. PubMed ID: 21970659
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.
Patel JJ; Mendes MA; Bounthavong M; Christopher ML; Boggie D; Morreale AP
J Eval Clin Pract; 2012 Apr; 18(2):247-55. PubMed ID: 20846318
[TBL] [Abstract][Full Text] [Related]
13. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
de Gramont A; Van Cutsem E
Oncology; 2005; 69 Suppl 3():46-56. PubMed ID: 16301835
[TBL] [Abstract][Full Text] [Related]
14. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer.
Minion LE; Bai J; Monk BJ; Robin Keller L; Ramez EN; Forde GK; Chan JK; Tewari KS
Gynecol Oncol; 2015 Jun; 137(3):490-6. PubMed ID: 25766118
[TBL] [Abstract][Full Text] [Related]
15. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer.
Lin S; Luo S; Zhong L; Lai S; Zeng D; Rao X; Huang P; Weng X
Int J Clin Pharm; 2020 Aug; 42(4):1175-1183. PubMed ID: 32524512
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
Sandler A; Gray R; Perry MC; Brahmer J; Schiller JH; Dowlati A; Lilenbaum R; Johnson DH
N Engl J Med; 2006 Dec; 355(24):2542-50. PubMed ID: 17167137
[TBL] [Abstract][Full Text] [Related]
18. First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China.
Yang Z; Zhu Y; Xiang G; Hua T; Ni J; Zhao J; Lu Y; Wu Y; Chang F
Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):1061-1067. PubMed ID: 33682554
[No Abstract] [Full Text] [Related]
19. Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective.
Thongprasert S; Tinmanee S; Permsuwan U
Asia Pac J Clin Oncol; 2012 Mar; 8(1):53-61. PubMed ID: 22369444
[TBL] [Abstract][Full Text] [Related]
20. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis.
Cohn DE; Kim KH; Resnick KE; O'Malley DM; Straughn JM
J Clin Oncol; 2011 Apr; 29(10):1247-51. PubMed ID: 21383297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]